Yolk sac development Phosphate transport
Introduction
PiT-1 (Slc20a1) protein is a sodium-dependent phosphate (Pi) transporter that contains 12 transmembrane domains (Farrell et al., 2009; O'Hara et al., 1990) . PiT-1 was first identified as the gibbon-ape leukemia virus receptor (Glvr1), and found to function as a sodium-dependent phosphate transporter (Johann et al., 1993; Kavanaugh and Kabat, 1996; Kavanaugh et al., 1994; Olah et al., 1994; Virkki et al., 2007) . Inorganic phosphate (Pi) is required in high abundance for http://dx.doi.org/10.1016/j.mod.2014.08.001 0925-4773/Ó 2014 Elsevier Ireland Ltd. All rights reserved. numerous biological processes including nucleic acid synthesis, mineralization, oxidative phosphorylation and many others. PiT-1 facilitates Pi uptake against the electrochemical gradient via Na-coupled exchange. PiT-1 has also been implicated in terminal B-cell and erythrocyte cell differentiation, as well as cell cycle progression (Beck et al., 2009; Byskov et al., 2012; Forand et al., 2013; Liu et al., 2013) . PiT-1 KO embryos are embryonic lethal and display gross defects in yolk sac (YS) vascular development and hematopoiesis (Beck et al., 2010; Festing et al., 2009) .
Mammalian embryonic development is highly dependent upon regulated maternal-fetal exchange. Initially, the growth of the embryo is largely self-sustaining. However, as development proceeds further, growth of the embryo requires formation of the YS. The YS isolates the embryo from the uterine lumen and facilitates uptake of maternal factors, including immunoglobulins, LDL, transferrin, and other identified and unidentified molecules by both endocytosis, in which molecules are delivered to a specialized lysosome called the apical vacuole (AV), as well as transcytosis in which molecules are transferred across cells. Presumably maternal Pi is included in these processes, but this remains to be clearly demonstrated in mammals. The YS contains two tissue layers: the mesodermal layer (ME), and the visceral endoderm (VE) layer which is a transporting epithelium that serves nutritive and metabolic functions (Jollie, 1990; Palis, 2005) . The YS VE layer is derived from the primitive endoderm of the blastocyst. As the embryo develops, distal primitive endoderm gives rise to the embryonic visceral endoderm layer (emVE) and proximal primitive endoderm differentiates into the extraembryonic visceral endoderm layer (exVE) that undergoes transcytosis at embryonic day (E) 5.25-E6.5 (Viotti et al., 2012) . The exVE then gives rise to the YS VE layer that undergoes yolk sac trafficking after E7.5 (Viotti et al., 2012) . The ME layer is generated from cells in the posterior primitive streak during gastrulation after $E6.5 (Viotti et al., 2012) .
Several key players in YS endocytosis are known, but the inductive factors and many mechanistic steps are yet to be discovered. Recently published work indicates that endocytosis in the VE occurs at least in part via microautophagy in which microvesicles (MVs) containing maternal factors are endocytosed (Kawamura et al., 2012; Wada et al., 2013) . The resulting intracellular double membrane organelle fuses with the AV and the MV is delivered into the AV lumen. Finally, the MV membrane and the contents of the MV are hydrolyzed (Kawamura et al., 2012; Wada et al., 2013) .
A fully developed YS vasculature is absolutely required for survivability of the embryo. YS development is initiated during gastrulation. First, blood islands are formed in the mesodermal tissue adjacent to the VE in the proximal, extraembryonic region of the gastrulating mouse embryo by $E7.5 (Palis et al., 1995) . Next, the blood islands fuse via vasculogenesis to generate a network of primitive vessels known as the vascular plexus by E8.0 (Ema and Rossant, 2003; Palis, 2005) . The vascular plexus is then ''remodeled'' via angiogenesis into a mature vasculature by E10.0 (Palis, 2005) . Although the VE directly mediates maternal-fetal communication, the underlying mesodermal layer (ME) is the site of YS vascular development. The complex morphogenetic vascular development that occurs within the ME is highly dependent on the presence and normal activity of the VE (Palis et al., 1995) . Disruption of the remodeling process frequently results from loss of molecular signaling pathways that promote normal endothelial and hematopoietic cell differentiation and morphogenesis intrinsic to the YS tissue, including paracrine VE to ME signaling (Ema and Rossant, 2003; Goldie et al., 2008; Ueno and Weissman, 2010) . Alternatively, a loss of mechanical stimulation/hemodynamic force due to upstream aberrant cardiac function also leads to defective YS remodeling (Culver and Dickinson, 2010; Lucitti et al., 2007) . Lethality associated with abnormal yolk sac vascular development commonly occurs between E9.5 and E12.5. The role of Pi in the development and function of the YS has not yet been elucidated.
PiT-1 knock out (KO) embryos die by E12.5 from largely unknown causes, indicating that PiT-1 is necessary for embryonic development (Beck et al., 2009; Festing et al., 2009) . Additionally, the time frame of PiT-1 KO embryonic death corresponds with that of yolk sac malfunction mortalities. However, the specific role of PiT-1 in the YS remains unknown. We have found that vascular smooth muscle cell (VSMC) knock down (KD) of PiT-1 in vitro decreases several processes, including Pi uptake, mineralization, and osteochondrogenic phenotype change in high Pi conditions (Li et al., 2006) . Furthermore, others have recently shown that PiT-1 is required for homeostatic levels of autophagy; vesicular shedding in VSMCs is thought to be counteracted by Pi-induced ROS production that promotes autophagy in non-disease conditions (Dai et al., 2013) . These in vitro analyses suggest that there may be an important role for PiT-1 in autophagy in vivo. In order to elucidate the in vivo roles of PiT-1, we have taken advantage of complete and tissue specific PiT-1 KO mouse lines. Here we present data supporting that PiT-1 is required for Pi-mediated endocytosis via microautophagy in the yolk sac visceral endoderm.
2.
Experimental procedures 2.1. Mice: embryo production, genotyping and yolk sac tissue layer collection
For production of PiT-1 KO and control WT animals, heterozygous PiT-1 mice were mated. For production of SM22a-KO animals, PiT-1 fl/fl females and PiT-1 fl/fl, SM22aCre males were mated. SM22aCre mice were kindly provided by Dr. David Dichek (University of Washington). Timing of embryonic development was determined by the presence of a vaginal plug the morning after mating and designated as E0.5. At the time of embryonic collection, female mice were euthanized and embryos and extraembryonic tissues were collected by mechanical dissection in PBS.
At the time of dissection posterior embryonic trunk and tail were taken for genotyping. DNA extraction was performed using Proteinase K (Sigma P6556). WT and KO embryos were genotyped with established methods (Festing et al., 2009) , and PiT-1 fl/fl and fl/fl,cre (SM22a-KO) embryos were genotyped with established methods . Primer sequences and PCR conditions are listed in Supplemental Table 1 .
The yolk sac layers were separated using the trypsin/pancreatin method as described in (Rhee et al., 2013) . Briefly, yolk sacs were collected and incubated in Tyrode Ringers Solution (Fisher S25512) containing 0.005 g/mL Trypsin (Fisher S25618) and 0.025 g/mL Pancreatin (Fisher S25456) for 4 h at 4°C with gentle shaking. Yolk sacs were then washed in DMEM (Life Technologies 11995-065) and tissue layers were mechanically separated and stored at À80°C until further processing.
2.2.
Gene expression: RNA extraction, cDNA synthesis, RT-PCR and qPCR Embryonic tissues, whole yolk sacs or yolk sac layers were dissected and stored at À80°C. Total RNA was extracted using the RNeasy Mini Kit (Qiagen 74104) and DNaseI (Qiagen 1023460). cDNA synthesis was performed with 500 ng of whole yolk sac RNA, 250 ng of specific yolk sac tissue layer RNA or 250 ng of embryonic heart RNA. For reverse transcription the Omniscript RT Kit (Qiagen 205113) was used with both oligodT primers (Promega C110A) and random hexamers (Qiagen 79236) according to the manufacturer's instructions.
RT-PCR was performed as in 
Histology

Fixation, embedding and sectioning
Embryonic tissue was processed as in (Trask et al., 2012) . Samples were dissected and fixed in 4% paraformaldehyde (PFA)/PBS overnight at 4°C. They were then dehydrated through a series of methanol washes, treated with xylenes, embedded in paraffin and sectioned at 7.5 micrometers with a Leica RM2135.
Immunostaining
IImmunofluorescence was performed as in , but treated with a serum block as opposed to a milk block. PiT-1 immunohistochemistry was performed as in with chicken anti-rat PiT-1 primary antibody (provided by Dr. M. Levi, University of Colorado), Tris Base heat-mediated antigen retrieval and donkey serum block. Slides were counterstained with Harris Hematoxylin (Sigma HHS32).
Whole mount Pecam1 staining was performed with rat anti-CD31 (BD PharMingen 550274), 4% BSA block, and goat anti-rat secondary antibody (Jackson ImmunoResearch 712-035-153).
H&E
Slides were stained with Harris Hematoxylin (Sigma HHS32) and counterstained with Eosin Y (Sigma E4382).
Image analysis
Digital images of whole mount embryos were captured on a Nikon SMZ-1500 stereomicroscope equipped with a Nikon D5100 DSLR camera. Digital images of sectioned embryos were taken with a Nikon Eclipse E800 inverted fluorescence microscope and RS Photometrics Coolsnap color digital camera, imaged with Metamorph Version 6.3r7 and converted with Irfanview Version 4.2.3. The Image-J version 1.46r (http://imagej.nih.gov/ij) ROI Manager Tool and the Image-J ''Cell Counter'' plug-in was used to assist with cell counting and cell height measurements. For cell height measurements, images of H&E stained yolk sac sections where used and were assessed blindly; the images had coded names and the measurer had no knowledge of the sample genotypes or any previous experience with the images. Twenty cells from each of three images were counted for three different yolk sacs for each genotype (180 cells total per genotype). For maximum artery width quantification, the three largest arteries on three images per yolk sac were measured with ImageJ; a total of three yolk sacs per genotype were examined. In order to determine the extent of endocytosis of phRODO Dextran, ImageJ was used to blindly determine the internal density value of ten cells for each of ten images/yolk sac; the normalization value was taken by averaging three readings and normalized internal density values for each yolk sac were calculated prior to genotyping. The student's t-test was used to test the null hypothesis that there are no differences between control and KO samples.
Western blotting
For western blotting, yolk sac lysates were collected and treated with a protease inhibitor cocktail (Roche). Lysates were denatured in Laemli Buffer containing b-Mercaptoethanol and run in a 10% SDS Page gel. LC3A antibody (Cell Signaling Technology D50G8 XP) was used according to the manufacturers instructions. The western blot was stripped with Restore Plus Western Blot Stripping Buffer (Thermo Scientific PI-46430). bÀActin (Abcam ab8227) was used to determine a loading control. Densitometry was performed with ImageJ. PiT-1 antibody (see Section 2.3) was used to confirm loss of PiT-1 protein.
ex vivo Yolk Sac Assays
Optimal dilutions of both Lysotracker Red (Life Technologies DND99) and phRODO Green Dextran for Endocytosis (Life Technologies P35368) were determined empirically (Supplemental Figs. 2 and 3). Yolk sacs were dissected in PBS. For visualization of vacuoles, the lysosome stain Lysotracker Red was incubated at 1:1000 in PBS for 5 min at 37°C. Upon receipt, phR-ODO Dextran was resuspended according the manufacturer's instructions and stored at À20°C. Working solutions of phROD-O Dextran were made by diluting stock solution in prewarmed DMEM with 10%FBS at 1:100 and yolk sacs were incubated for 2 h at 37°C. Yolk sacs were immediately mounted in Prolong Gold (Life Technologies P36930) and imaged.
Results
Na-dependent phosphate transporter gene expression
Our lab previously identified that PiT-1 KO embryos display embryonic lethality and gross vascular abnormalities at E12.5 (Festing et al., 2009) . We began to follow up on this research by assessing gene expression of PiT-1 and PiT-2 in WT and PiT-1 KO yolk sacs by qPCR (Fig. 1) . We observed a lack of WT PiT-1 mRNA in PiT-1 KO embryos as compared to WT embryos (p-value = 0.000405) (Fig. 1A) . Unlike other PiT-1 KO models, PiT-2 expression was not significantly increased in the PiT-1 null YS (p-value = 0.065123) (Fig. 1B) . PiT-1 and PiT-2 expression in the developing yolk sac were previously examined by RT-PCR and Southern blotting with conflicting results (Festing et al., 2009; Richardson and Bank, 1996) . In order to address this issue we examined PiT-1 and PiT-2 expression during yolk sac development by qPCR. We found that both genes are expressed throughout development in the yolk sac. PiT-1 expression peaked at E9.5, and PiT-2 expression increased linearly with development (Fig. 1C,D) . Finally, PiT-1 protein was strongly localized to the apical VE in E9.5 YS (Fig. 1E,F) .
3.2.
PiT-1 KO results in a yolk sac remodeling defect At E9.5 both WT and PiT-1 KO embryos and yolk sacs look largely normal ( Fig. 2A,D) . Both display a beating heart and subsequent blood flow (data not shown). Primitive erythropoietic progenitors can be seen within the yolk sac vasculature in whole mount samples (circles in Fig. 2A,D) and in H&E stained yolk sac sections (arrows in Fig. 2B,E) . However, whole mount staining of endothelial Pecam1/CD31 (Baldwin et al., 1994) at E11.5 reveals a characteristic remodeling defect in PiT-1 KO YS, evidenced by the failure of the hatched vascular plexus (asterisk in Fig. 2C ) to develop into a mature branching vasculature (asterisk in Fig. 2F ) with large arteries (arrows in Fig. 2C,F) . Maximum artery width measurements further support the failure of normal vascular development in the PiT-1 KO YS (Fig. 2G-I) . In order to test whether developmental signaling pathways were disrupted in the PiT-1 KO YS, RT-PCR with WT and KO E11.5 YS RNA was performed and we found that expression was maintained for all VE to ME signaling pathways examined (Supplemental Fig. 1 ). VE genes Hnf4a Duncan et al., 1994) , Tgfb1 (Akhurst et al., 1990) and Vegfa (Breier et al., 1995) were increased in PiT-1 KO YS, but most ME genes examined, including Acta2 (Mahlapuu et al., 2001) , Tagln (Li et al., 1996) , TgfbrII (Wang et al., 1995) , Flk1 (Nishikawa et al., 1998) , and Tie2 (Mahlapuu et al., 2001) were largely unaltered (Supplemental Fig. 1 ).
3.3.
Deletion of PiT-1 in SM22a expressing cells of the developing heart does not result in embryonic lethality Defects in YS angiogenesis or remodeling are commonly attributed to an upstream cardiac defect resulting in a lack of hemodynamic pressure, or defective developmental signaling. In order to determine whether there could be an upstream cardiac requirement for PiT-1 we turned to a tissue-specific knock out system. Our lab previously produced mice in which PiT-1 exons 3 and 4 are floxed by loxp sites (PiT-1 fl/fl) (Festing et al., 2009) . We then bred PiT-1 fl/fl mice to SM22aCre mice to produce KO of PiT-1 in SM22a expressing cells; these mice are viable, reproduce normally and do not show heart abnormalities when analyzed by ultrasound .
SM22aCre activity was shown previously in detail through the use of R26R mice; at E8.5 SM22aCre is active in a small number of cells in the primitive heart and ME layer of the YS, and at E9.5 SM22aCre is active throughout the developing heart and the ME layer of the YS (French et al., 2008) . In order to determine the extent of Cre mediated loss of PiT-1, we collected E9.5 and E10.5 hearts and examined expression of SM22a, Cre and PiT-1 mRNA (Fig. 3C, D) . SM22a expression confirmed isolation of target tissue. Cre expression was only observed in the SM22a-KO heart RNA and not the fl/fl control heart RNA. As expected, PiT-1 expression was largely reduced in the SM22a-KO developing hearts. We then isolated E11.5 control PiT-1 fl/fl embryos and PiT-1 fl/fl, SM22aCre (SM22a-KO) embryos to examine YS vasculature and found that the SM22a-KO develop a mature YS vasculature with large hierarchical vessels by E11.5 (Fig. 3A,B) .
We next examined gene expression in E9.5 and E10.5 yolk sac VE and ME tissue layers that had been separated by enzymatic and mechanical methods as outlined in the Section 2. Expression of the ME marker Flk1 and the VE marker Hnf4a were used to confirm effective tissue separation. Again, Cre expression and reduced PiT-1 levels were specifically observed in the expected tissue (SM22a-KO ME) at E9.5 and E10.5 (Fig. 3E,F) .
Altered endocytosis gene expression and IgG accumulation in PiT-1 KO YS
To identify the upstream cause of the PiT-1 KO YS vascular development phenotype, we examined the gross morphology of E9.5 WT and KO YS by analyzing H&E stained sections. We identified a focal disruption of normal nuclear localization relative to the apical and basal cell membranes in the PiT-1 KO YS VE. To assess proliferation, PCNA staining and DAPI counterstaining of WT and PiT-1 KO E9.5 YS sections was performed and did not reveal a gross difference in PCNA levels (data not shown). In epithelial cells E-Cadherin (CDH1) is absent from the apical membrane (Jenkins et al., 2013) . We examined CDH1 localization in WT and PiT-1 KO E9.5 YS sections; VE/ME cells were delineated with the help of the ME marker SM22a (Fig. 4) . Both WT and PiT-1 KO VE apical cell membranes were found to be E-Cadherin negative, suggesting normal cell polarity (arrows in Fig. 4) .
We then hypothesized that the nuclei appeared more centrally located due to a decrease in the height of the VE cells. Height and nuclear localization in WT and PiT-1 KO YS were quantified by performing blind measurements of total cell height and the cell height superficial to the nucleus in three different H&E stained sections from three different WT and KO yolk sacs for a total of 180 cells/genotype (Fig. 5A-C) . The average height of E9.5 WT VE cells was significantly larger than the PiT-1 KO cells (WT = 17.03 lm vs KO = 14.82 lm; pvalue = 0.0018), as was the apical height (WT = 7.12 lm vs KO = 5.12 lm; p-value = 0.00014) (Fig. 5B) . Together these data indicate that the total height is shorter in the PiT-1 KO VE, and this difference is due to a decrease in the height of the apical space of the cell.
In WT YS VE the apical side of the cell contains specialized lysosomes termed apical vacuoles (AV). Maternal IgG and other molecules are normally taken up by the VE and delivered to the AV. We examined uptake of maternal IgG in WT and KO yolk sacs and observed a striking reduction in IgG staining on the PiT-1 KO YS (compare Fig. 5D -G to H-K). This loss of IgG localization suggests a functional endocytosis defect and/or a structural AV defect.
In order to assess whether endocytosis and/or microautophagy was disrupted, we examined YS layer-specific expression of several genes related to endocytosis or autophagy including LC3, Tfeb, Lamtor2 and Snx2 (Kabeya et al., 2000; Griffin et al., 2005; Sardiello et al., 2009; Schwarz et al., 2002; Settembre et al., 2011; Sparber et al., 2013; Teis et al., 2006) . As expected we found that the expression of these genes was largely restricted to the VE layer (Fig. 6A) . Tfeb, a master transcriptional regulator of both endocytosis and autophagy genes was expressed throughout YS development and the important autophagy-related gene LC3 was expressed in a stage specific manner during YS development (Fig. 6B) . Fig. 1 -PiT gene expression. At E11.5 PiT-1 mRNA is absent from the KO YS (A) and there is no significant difference in PiT-2 expression (B) by qPCR (N = 3/genotype). Developmental profiles of PiT mRNA during YS development collected by qPCR show a peak in PiT-1 expression at E9.5 (C) and a linear increase of PiT-2 expression (D) (N = 3/embryonic stage). PiT-1 protein localizes to the apical membrane of YS VE at E11.5 (E) compared to a no primary control (F). Scale bars = 25 lm.
Tfeb, LC3, Lamtor2 and Snx2 were upregulated in the PiT-1 KO YS VE at the RNA level (Fig. 6C1,C2) . In order to quantify the level of autophagy in the YS, we examined expression of LC3 protein in the yolk sac. LC3-I is the unmodified protein that is found in the cytosol, and LC3-II is cleaved protein that localizes to the autophagosome and is representative of the degree of autophagy. The level of autophagy determined by LC3-II/LC3-I ratios was significantly decreased in the PiT-1 KO YS (p-value = 0.037), and the overall LC3 protein levels normalized to b-Actin were modestly decreased (p-value = 0.06) (Fig. 6D1, quantified by densitometry in D2) .
In order to test for vacuole presence we dissected fresh yolk sacs and incubated them with the lysosome stain Lysotracker Red according to the manufacturers instructions (Fig. 7A-D) . This stain clearly demonstrated a loss of normal lysosome presence in the PiT-1 KO YS. We then examined endocytosis in dissected yolk sacs ex vivo with the use of the phRODO Green Dextran for Endocytosis. This functional assay demonstrated a significant decrease in endocytosis in the PiT-1 KO (Fig. 7E-I ).
Discussion
Our results shed light on the requirement for PiT-1 in yolk sac endocytosis. A loss of global PiT-1 results in abnormal VE gross morphology, decreased maternal-fetal IgG uptake, upregulation of endocytosis and autophagy gene transcription, disruption of AV maintenance and decreased endocytosis ex vivo. This data supports that normal endocytosis in the YS requires PiT-1. We hypothesize that the absence of PiT-1 leads to a decrease in endocytosis and lysosomal activity that in turn results in a failure of the VE to appropriately support the ME layer during yolk sac angiogenesis (Fig. 8) . In conjunction with published literature our data prompts additional Fig. 2 -PiT-1 KO vascular remodeling defect. At E9.5 PiT-1 KO embryos are largely normal. Yolk sac vasculature is visible (circles in A, D) and H&E stained YS sections reveal presence of nucleated erythrocytes (arrows in B,E). However, whole mount IHC of Pecam1 at E11.5 shows a clear yolk sac remodeling defect, including absence of a mature branching vasculature (asterisks in C,F) and large arteries (arrows in C,F). Quantification of this by measurement of maximum artery width (described in Section 2) revealed a significant difference between the average WT artery width (120.9 lm ± 39.1 lm) and the average PiT-1 KO artery width (64.2 lm ± 14 lm) (G-I) (N = 3/genotype). Scale bars: A and D = 1 mm; B and E = 100 lm; C,F,G and J = 500 lm.
questions about PiT-1 activity in both developmental and disease models.
Working model of Pi-mediated endocytosis
The data presented here begs the question of whether PiT-1 is required for endocytosis via microautophagy. High Pi and reactive oxygen species (ROS) induce homeostatic levels of autophagy that are believed to counteract vesicle shedding in cultured human vascular smooth muscle cells (HA-VSMCs); as would be predicted, HA-VSMC PiT-1 KD in vitro results in decreased autophagy (Dai et al., 2013) . Similarly, we found that KO of PiT-1 results in decreased autophagy in the PiT-1 KO YS. This novel regulation of endocytosis by a phosphate transporter highlights the importance of Pi localization during development. However, the dynamics of uptake and endocytic cycling of Pi in the YS remains unknown.
The data supports that endocytic cycling in disrupted in the PiT-1 KO VE and manifests in altered epithelial cell morphology, endocytosis and autophagy. This implies that despite the expression increase of both Tgfb1 and Vegfa RNA in the PiT-1 KO VE, these important paracrine signaling molecules Tgfb1 and Vegfa do not successfully reach their respective receptors that are localized to cells in the ME layer. Therefore, the increased expression does not have an effect on the ME layer, and it is instead the lack of normal endocytic processes that impact yolk sac development. This work is the first to suggest connections between Pi uptake, endocytosis, and paracrine support of vascular development. Pi uptake in this case may be directly through PiT-1, or indirectly through a currently unidentified mechanism. Additionally, it is possible that both the abnormal cellular morphology and the endocytosis failure involve Pi-dependent defects in the cytoskeletal network. Further research will elucidate the specific role of Pi uptake in this system, as well as the direct impact of Pi uptake and Pi deprivation on endosome trafficking and the cytoskeletal network.
In the absence of PiT-1 endocytosis and autophagy genes are upregulated in the VE, possibly through a compensatory mechanism. Although RNA levels are high, it is likely that proteins are not functioning normally. In support of this idea, we found a decrease in LC3 protein by western blotting, despite an increase in LC3 RNA. This indicates that the increased RNA levels may indeed reflect a compensatory mechanism attempting to counteract the loss of endocytosis and autophagy in the PiT-1 KO YS. Snx2 shuttles CIMPR in yeast and other cell types. Of note, the Snx1/2 double KO is lethal due to YS malfunction that includes VE AV defects, yet Snx2 does not shuttle CIMPR in the YS as it does in yeast -the specific role of Snx2 in the YS remains enigmatic (Griffin et al., 2005; Schwarz et al., 2002) . Therefore, it is possible that Snx2 shuttles PiT-1 or a microautophagy-related protein between the apical cell membrane, endosomes, apical vacuoles and mitochondria.
Lastly, the mechanistic step between Pi uptake and microautophagy induction is not clear. Mitochondria are LC3 is expressed in a stage specific manner during YS development and Tfeb is expressed at similar levels during YS development (B). YS VE RT-PCR of isolated YS VE mRNA reveals an upregulation of LC3, Tfeb, Lamtor2 and Snx2 in PiT-1 KO YS VE compared to heterozygous controls (C1, analyzed by densitometry in C2). Western blotting of LC3, B-Actin and PiT-1 reveals a slight decrease in total LC3 protein as well as a decrease in autophagy in PiT-1 KO yolk sacs identified by the ratio of LCII/LCI expression (D1, analyzed by densitometry in D2). Het: heterozygous. NS: nonspecific band. E8.5 * : E8.5 allantois. well-known sites of the electron transport chain and oxidative phosphorylation. Interestingly, Vamp1 (also known as Synaptobrevin1) may play a role in Pi-dependent endocytosis. Vamp1 is expressed in the YS and closely parallels expression of PiT-2 in the brain (da Silva et al., 2013) . Vamp1 spliceisoforms vary in sequence and function. Vamp1a targets the plasma membrane and mediates exocytosis in neuronal cells and cardiomyocytes. Importantly, the splice-isoform Vamp1b targets the mitochondria (Isenmann et al., 1998) . We found that Vamp1b expression exceeds Vamp1a expression in the YS, and increased at a higher rate during YS development (data not shown). This novel data leads us to speculate that Vamp1b could potentially mediate delivery of Pi or other vesicle contents to mitochondria in PiT expressing cells. Together these data suggest a working model of endocytosis in which PiT-1 promotes Pi delivery to mitochondria, thus inducing ROS production and microautophagy. Future studies examining Pi dynamics, ROS levels and Vamp1 activity in PiT-1 KO YS will help differentiate these possibilities.
4.2.
Tissue-specific transporter function Previously, our lab found that PiT-2 is increased in PiT-1 null VSMCs . Additionally, PiT-1 compensation has been suggested as a potential pathogenic mechanism for development of familial idiopathic basal ganglia calcification (FIBGC) in human cases associated with mutated PiT-2 sequences (da Silva et al., 2013; Hsu et al., 2013; Wang et al., 2012; Zhang et al., 2013) . For these reasons, the mechanisms controlling compensatory PiT expression are of interest. Notably, we have found that the PiT-1 global KO did not cause a significant increase in PiT-2 RNA in whole YS lysates.
Of note, PiT-2 RNA is expressed, indicating a PiT-1 specific role at this stage of embryonic development. This data suggests that compensatory PiT-1 and PiT-2 gene expression is cell type-dependent, and further suggests that PiT-1 plays a specific role in yolk sac development for which PiT-2 is not capable of compensating. Conversely, SM22a-KO mice are viable despite the altered PiT-1 expression in the developing heart and ME layer. This suggests that either of the type III transporters may be sufficient to fulfill requirements for type III sodium-dependent phosphate transporters in SM22a positive lineages. Importantly, a low level of PiT-1 expression was observed in the SM22a-KO hearts and YS ME layer. This expression most likely originates from the developing endocardium of the heart, and the endothelium and primitive blood cells of the YS ME layer; the work presented here does not distinguish between these possibilities. Examination of Pi-uptake dynamics as well as tissue specific single and double PiT-1 and PiT-2 KO will yield valuable information about the complex interplay of these two genes and their potential roles in vascular development and disease.
4.3.
PiT-1 and vascular disorders
The PiT-1 global KO phenotype we have observed, coupled with the contrasting viability of PiT-1 SM22a-KO mice suggests that PiT-1 may be required in the YS VE, but either PiT-1 or PiT-2 may subserve type III transporter requirements in SM22aCre expressing tissues. Work aimed at understanding mechanisms of vascular calcification has revealed a compensatory increase in PiT-2 gene expression in mature vasculature of the adult. PiT-1 is believed to play a role in vascular calcification in patients with chronic kidney disease (CKD), in which ectopic hydroxyapatite In WT animals PiT-1 is present on the apical VE membrane, phosphate is taken into the cell (1), high Pi induces mitochondrial production of ROS (2) and vesicular uptake (3). As a result nutrients are delivered to the apical vacuole via microautophagy (4), and healthy VE promotes vascular development in the mesodermal layer (5). (B) In the PiT-1 KO Pi levels are not maintained, IgG does not properly accumulate in the AV, Snx2, Lamtor2, LC3 and TFEB are upregulated at the transcriptional level, LC3 protein is lost, and impaired VE endocytosis inhibits appropriate ME vascular development. Pi: inorganic phosphate. EE: early endosome. LE: late endosome. LC3-A: LC3-II associated autophagosome. AV: apical vacuole. Mito: mitochondria.
formation may lead to vessel stiffening and mortality. Elevated serum Pi is a key risk factor for vascular calcification (Dhingra et al., 2007; Kestenbaum et al., 2009; Tonelli et al., 2009 ) and when VSMCs are exposed to high Pi, calcification is observed (Jono et al., 2000; Lomashvili, 2004) . This data suggests that Pi-driven mechanisms may control ectopic calcification observed in patients with CKD (Lau et al., 2010; Shanahan et al., 2011) . KO of PiT-1 in human cells alleviated calcification (Li et al., 2006) . However, we found that KO of PiT-1 in mouse cells failed to act similarly and instead resulted in an increase of PiT-2 expression both in vitro and in vivo in the aorta of CKD mouse models . Furthermore, in vitro expression of PiT-2 in PiT-1 null cells revealed that PiT-2 was capable of compensating for PiT-1 with respect to Pi uptake and calcification . As PiT-2 was able to compensate for Pi transport in PiT-1 KD human VSMC, both type III transporters may play critical roles in ectopic mineralization. Currently, the specific mechanistic steps remain enigmatic. Furthermore, abnormal levels of PiT gene expression may promote FIBGC. Large subsets of patients with FIBGC were recently found to contain deleterious mutations in PiT-2 (da Silva et al., 2013; Hsu et al., 2013; Wang et al., 2012; Zhang et al., 2013) , which has been suggested to result in compensatory PiT-1 overexpression and subsequent disease-related calcification. Interestingly, PiT-1 is not capable of compensating for loss of PiT-2 in FIBGC. This indicates a PiT-2 specific requirement and further supports the presence of distinct roles for each type III transporter.
Conclusions
We have found that global PiT-1 KO results in a YS remodeling/angiogenesis defect early in development. However, Sm22aCre mediated tissue-specific PiT-1 KO mice are viable and display high decreased levels of PiT-1 loss in the developing heart and YS ME layer. The viability of PiT-1 SM22a-KO mice supports that the PiT-1 global KO YS remodeling defect observed at E11.5 is not due to an upstream cardiac requirement for PiT-1. At E9.5, prior to disruption of normal developmental gene expression, maternal IgG accumulation in the AV is lost and mRNA of several endocytosis and autophagy genes is increased in the PiT-1 KO VE, likely reflecting a compensatory mechanism. LC3 protein levels are decreased, and Lysotracker Red confirms that AV maintenance is disrupted. Lastly, we find that uptake of fluorescent dextran is disrupted in an ex vivo functional endocytosis assay performed with dissected yolk sacs. Together, this data supports the novel idea that PiT-1 is required for endocytosis in the yolk sac. Additionally, this work suggests that there are tissue-specific differences in the roles of PiT-1 and PiT-2 in vivo.
